Grandevo® CG and Venerate® CG Are Effective Tools for Controlling Economically Damaging Mites and Insect Pests
DAVIS, Calif., June 28, 2018 (GLOBE NEWSWIRE) — Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, is pleased to announce that GRANDEVO CG and VENERATE CG have been approved for use on Cannabis by the Alaska, Colorado, Oregon, Nevada, and Washington Departments of Agriculture.
The active ingredients in VENERATE CG and GRANDEVO CG bioinsecticide/miticides are each new species of non-living bacteria with insecticidal and miticidal properties produced during the fermentation manufacturing process. Both products feature multiple modes of action that are complementary to one another. This complex activity makes the products excellent additions to insect and mite management programs, which allows the two products to be used alone or in a rotational crop protection program. Both products can be used right up to harvest and have the shortest re-entry period (4 hours). Cannabis growers have been adopting VENERATE CG and GRANDEVO CG for control of bud mites and aphids.
VENERATE CG and GRANDEVO CG are both USDA National Organic Program certified and Organic Materials Review Institute (OMRI) listed for use in organic farming. Additionally, they are exempt from food tolerance requirements in the United States, which means that the use of VENERATE CG and GRANDEVO CG does not trigger pesticide residue risk concerns for workers and consumers.
“Grandevo and Venerate are game changers when it comes to IPM programs. I have eliminated all other preventive sprays and now only use Grandevo and Venerate,” said Kyle Stamback, Lean Cultivation NorthWestGrown i502. “I have had great results against all types of malice bugs, from leaf eaters to root aphids, and these products have kept my gardens clean and my beneficial bugs happy.”
“We are pleased that the Alaska, Colorado, Oregon, Nevada and Washington Departments of Agriculture determined that GRANDEVO CG and VENERATE CG meet the state’s criteria for use on Cannabis, and we look forward to working with growers and distributors to serve these exciting new markets with our existing product portfolio as well as our future innovations,” stated Lisa Malabad, Cannabis Segment Lead at Marrone Bio Innovations.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc. (NASDAQ:MBII) strives to lead the movement to more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies to rapidly develop seven effective and environmentally responsible pest management products to help customers operate more sustainably while uniquely improving plant health and increasing crop yields. Supported by a robust portfolio of over 400 issued and pending patents around its superior natural product chemistry, MBI’s currently available commercial products are Regalia®, Grandevo®, Venerate®, Majestene®, Haven®, Stargus® and Amplitude™, Zelto® and Zequanox®.
Marrone Bio Innovations is dedicated to pioneering smart biopesticide solutions that support a better tomorrow for both farmers, turf managers and consumers around the globe. For more information, please visit www.marronebio.com.
Marrone Bio Innovations Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the potential of Grandevo CG and Venerate CG and other MBI products in the US and Canada, market projections, including the potential benefits of Regalia CG. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.
Marrone Bio Innovations Contacts:
Kevin Hammill, Chief Commercial Officer
Keith Pitts, Sr. VP of Regulatory and Government Affairs and Chief Sustainability Officer
Lisa Malabad, Product Marketing Manager and Cannabis Segment Lead
Telephone: +1 (530) 750-2800
MBI Investor Relations:
MZ Group – MZ North America